Elicio Therapeutics (ELTX) Net Cash Flow (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Net Cash Flow came in at -$3.6 million in Q1 2026, down 1831.1% YoY from $209000.0 in Q1 2025, and down 85.54% on a QoQ basis from -$2.0 million in Q4 2025.
Elicio Therapeutics (ELTX) Net Cash Flow (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Net Cash Flow data on file, last reported at -$3.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 1831.1% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (down 163.34% YoY) and the FY2025 annual result came in at -$273000.0, down 105.28% from the prior year.
- Net Cash Flow slipped to -$3.6 million in Q1 2026, from -$2.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $23.5 million in Q3 2024 to a low of -$15.7 million in Q1 2022.
- A 5-year average of $325529.4 and a median of -$1.1 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow jumped 554.16% — and 2026, when it tumbled 1831.1%.
- Tracing ELTX's Net Cash Flow over 5 years: stood at $3.8 million in 2022, then tumbled by 176.06% to -$2.9 million in 2023, then sank by 195.85% to -$8.6 million in 2024, then surged by 77.22% to -$2.0 million in 2025, then plunged by 85.54% to -$3.6 million in 2026.
- The last three Net Cash Flow figures came in at -$3.6 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 225.59 Mn |
| 10 | Elicio Therapeutics | 59.18 Mn | 35.68 Mn | - | 8.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.35 Mn |
| Jun 30, 2026 | 8.35 Mn |
| Mar 31, 2026 | -3.62 Mn |
| Mar 31, 2026 | -3.62 Mn |
| Dec 31, 2025 | -1.95 Mn |
| Dec 31, 2025 | -1.95 Mn |
| Sep 30, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.51 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Mar 31, 2025 | 209,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | -8.56 Mn |
| Dec 31, 2024 | -8.56 Mn |
| Sep 30, 2024 | 23.48 Mn |
| Sep 30, 2024 | 23.48 Mn |
| Jun 30, 2024 | -8.65 Mn |
| Jun 30, 2024 | -8.65 Mn |
| Mar 31, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.10 Mn |